Sartorius Stedim Biotech S.A.: Annual Report of the Liquidity Contract with the Stockbroker Company Gilbert Dupont
02 Janvier 2017 - 9:09PM
Business Wire
Regulatory News:
Under the liquidity contract concluded between Sartorius Stedim
Biotech S.A. (Paris:DIM) and the stockbroker Gilbert Dupont, the
following assets appeared on the liquidity account at December 31,
2016:
- Number of shares: 5,883
- Liquidity account cash balance: € 276,004.06
For information, the following assets appeared on the half-year
report of the liquidity contract of June 30, 2016:
- Number of shares: 2,744
- Liquidity account cash balance: € 469,908.75
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of
products and services that enable the biopharmaceutical industry to
develop and manufacture drugs safely and efficiently. As a total
solutions provider, Sartorius Stedim Biotech offers a portfolio
covering nearly all steps of biopharmaceutical manufacture. The
company focuses on single-use technologies and value-added services
to meet the rapidly changing technology requirements of the
industry it serves. Headquartered in Aubagne, France, Sartorius
Stedim Biotech is quoted on the Eurolist of Euronext Paris. With
its own manufacturing and R&D sites in Europe, North America
and Asia and an international network of sales companies, Sartorius
Stedim Biotech has a global reach. In 2015, the company employed
approx. 4,200 people, and earned sales revenue of 884.3 million
euros.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170102005145/en/
Sartorius Stedim Biotech S.A.Svenja Schildknecht,
+49(0)551.308.3232Investor
Relationssvenja.schildknecht@sartorius.com
WisdomTree International... (AMEX:DIM)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
WisdomTree International... (AMEX:DIM)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
Real-Time news about WisdomTree International MidCap Dividend Fund (American Stock Exchange): 0 recent articles
Plus d'articles sur Wisdomtree International Midcap Dividend Fund